Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.
Views & Analysis Geopolitical uncertainty grips digital health investors Galen Growth Asia has released its Q3 2019 Asia Pac HealthTech, aka digital health, ecosystem key trends interim report, which provides a checkpoint to bridge our mid-year and full year rep
Views & Analysis Nine for 2019: Opportunities for pharma In the last Nine for 2019 article, we reflected on the major challenges that are sha
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.